{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318623643392.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.1840150405"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.1840150405"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-199204000-00004"}},{"identifier":{"@type":"NAID","@value":"30026216523"}}],"dc:title":[{"@value":"A Randomized Controlled Trial of Lymphoblastoid Interferon–α in Patients With Chronic Hepatitis B Lacking Hbeag"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon–α in 60 patients with antibody to HBeAg and hepatitis B virus DNA-positive chronic hepatitis. Patients received 5 million U/m<jats:sup>2</jats:sup> interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.</jats:p>\n            <jats:p>The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody- and HBV DNA-positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584-589).</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670318623643397","@type":"Researcher","foaf:name":[{"@value":"Giovanna Fattovich"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643392","@type":"Researcher","foaf:name":[{"@value":"Patrizia Farci"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643396","@type":"Researcher","foaf:name":[{"@value":"Massimo Rugge"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643399","@type":"Researcher","foaf:name":[{"@value":"Lucio Brollo"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643393","@type":"Researcher","foaf:name":[{"@value":"Antonella Mandas"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643404","@type":"Researcher","foaf:name":[{"@value":"Patrizia Pontisso"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643400","@type":"Researcher","foaf:name":[{"@value":"Giuliano Giustina"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302172341822208","@type":"Researcher","foaf:name":[{"@value":"Eliana M. Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643403","@type":"Researcher","foaf:name":[{"@value":"Fabio Belussi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643401","@type":"Researcher","foaf:name":[{"@value":"Graziella Busatto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643402","@type":"Researcher","foaf:name":[{"@value":"Angelo Balestrieri"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643395","@type":"Researcher","foaf:name":[{"@value":"Arturo Ruol"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318623643394","@type":"Researcher","foaf:name":[{"@value":"Alfredo Alberti"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1992-04","prism:volume":"15","prism:number":"4","prism:startingPage":"584","prism:endingPage":"589"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.1840150405"},{"@id":"https://journals.lww.com/01515467-199204000-00004"}],"createdAt":"2007-03-04","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788892288","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided. 2. Treatment of the case which is negative in HBe antigen and repeats liver function abnormality."},{"@value":"ウイルス性慢性肝炎治療の最先端―治療方針に迷う症例に対する治療―２．ＨＢｅ抗原陰性，肝機能異常を繰り返す症例に対する治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204789394816","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical and antiviral effect of 28 times interferon administration therapy for chronic hepatitis B: Study on both patients with HBeAg and patients with antibody of HBeAg."},{"@value":"トランスアミナーゼ値の正常化とウイルスマーカーの改善を指標としたＢ型慢性肝炎におけるインターフェロン２８回投与の効果‐ＨＢｅ抗原陽性例とＨＢｅ抗体陽性例における検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205027668480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"HBVキャリア（変異株）の悪性リンパ腫3例に対するinterferon併用化学療法の試み"},{"@language":"en","@value":"Chemotherapy with Concomitant IFN Treatment in Three HBV Carriers (mutant strain) with Malignant Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206395941632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Twenty-four weeks administration of interferon-.ALPHA. for chronic hepatitis B."},{"@value":"Ｂ型慢性肝炎に対するインターフェロン２４週間投与の治療効果"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679767986432","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Examination of chronic administration of interferon for HBV-DNA positive chronic hepatitis type B."},{"@value":"ＨＢＶ‐ＤＮＡ陽性Ｂ型慢性肝炎に対するインターフェロン長期投与の検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679768791424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"Ｂ型慢性肝炎のインターフェロン療法"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1571417125025422848","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Evidence-based medicine on domestic data"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543024932307584","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105974409187072","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450568547968","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668925270635904","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Interferon and lamivudine monotherapy on chronic hepatitis B in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668926519536128","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.1840150405"},{"@type":"CIA","@value":"30026216523"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_NfXkHCo1j7qRADu2DMdw169fTA6"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_NfXkHCo1j7qRADu2DMdw169fTA6"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_NfXkHCo1j7qRADu2DMdw169fTA6"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_NfXkHCo1j7qRADu2DMdw169fTA6"}]}